Aldosterone: Direct Effects on and Production by the Heart
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The main effects of aldosterone, the most physiologically important mineralocorticoid, are on electrolyte transport across epithelia, particularly in the kidney, but also in other tissues, such as salivary glands and colon. Aldosterone acts to increase sodium (and consequently water) resorption and potassium excretion by directly or indirectly increasing the activity of epithelial sodium channels and sodium, potassium-adenosine triphosphatase (1). Aldosterone excess, whether from genetic causes or primary aldosteronism (hyperplasia or aldosterone-secreting adenomas), is well documented to cause hypertension. Hypertension, in turn, has significant adverse effects on the cardiovascular system, including left ventricular hypertrophy and cardiac fibrosis. Clinical evidence has been accumulating at an accelerating rate suggesting that aldosterone has direct adverse effects on the heart that are independent of its effects on blood pressure. Patients with primary aldosteronism are more likely to have left ventricular hypertrophy and stroke than patients with essential hypertension of comparable severity. More importantly, patients with severe heart failure have a 30% reduction in morbidity and mortality when given a mineralocorticoid receptor antagonist, spironolactone, in addition to conventional therapy of an angiotensin-converting enzyme (ACE) inhibitor, digoxin, and furosemide. The dose of spironolactone used in this study (25 mg) had no incremental effect on blood pressure, suggesting a direct cardioprotective effect (2). Remarkably, spironolactone had a significant beneficial effect only in patients with above median baseline levels of a marker of collagen synthesis, procollagen type III amino-terminal peptide. Elevated baseline levels of this peptide were associated with an increased risk of death and hospitalization, and circulating levels were decreased by spironolactone treatment. These results suggest that the limitation of cardiac fibrosis may be one of mechanisms by which spironolactone benefits patients with congestive heart failure (3).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steroidogenic enzyme gene expression in the human heart
Kayes-Wandover, K. M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.7.2519 · Cited by 174
Bassett, M., Zhang, Y., Clyne, C., White, P., & Rainey, W. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0280125 · Cited by 146
Self-citation
Cited by
Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones
Payne, A. H., & Hales, D. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0030 · Cited by 1,766
Jaffe, I. Z., & Mendelsohn, M. E. (2005) · Circulation Research · doi:10.1161/01.res.0000159937.05502.d1 · Cited by 358
Giacchetti, G., Ronconi, V., Turchi, F., Agostinelli, L., Mantero, F., Rilli, S., & Boscaro, M. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280108e6f · Cited by 196
Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0030 · Cited by 182
Markmann, S., De, B. P., Reid, J., Jose, C. L., Rosenberg, J. B., Leopold, P. L., Kaminsky, S. M., Sondhi, D., Pagovich, O., & Crystal, R. G. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.203 · Cited by 42
Metadata
- Authors
- White, P. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06-01
- Volume
- 88
- Issue
- 6
- Pages
- 2376-2383
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2030020451
- Cited by
- 97
- References
- 2
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aldosterone: Direct Effects on and Production by the Heart. https://app.cochat.ai/papers/10.1210/jc.2003-030373
- The paper
- White, P. C. (2003). Aldosterone: Direct Effects on and Production by the Heart. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-030373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.